Company intelligence / Profile preview

Novaliq GmbH

Ownership: Private
Development stage: Commercial

Overview

Novaliq has successfully developed and received FDA approval for two dry eye disease treatments: VEVYE™ (cyclosporine ophthalmic solution) 0.1% and MIEBO™ (perfluorohexyloctane ophthalmic solution). The company has a broad pipeline of products in various stages of development for glaucoma, retinal diseases, and other ophthalmic conditions[5][6].

Therapeutic areas: OphthalmologyEndocrinologyInfectious Diseases
Modalities: Small moleculespeptidesproteinsNCEs (New Chemical Entities)
Industry: Biotech

Drug pipeline

11 assets

NQ1910

Preclinical

10 more assets in the full pipeline.

Request access →

Partnerships

Not specifically named partners for commercialization in Europe and Australia/New Zealand for NovaTears®BLP Management Group (for Betaliq Inc.)

Beyond the preview

Go deeper on Novaliq GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novaliq GmbH.

Explore the full profile